Equity Overview
Price & Market Data
Price: $0.24
Daily Change: -$0.0049 / 2.04%
Daily Range: $0.239 - $0.252
Market Cap: $369,763,712
Daily Volume: 2,623,264
Performance Metrics
1 Week: -5.14%
1 Month: -17.24%
3 Months: -2.83%
6 Months: -4.00%
1 Year: -7.66%
YTD: 4.94%
Company Details
Employees: 25
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Northwest Biotherapeutics, Inc., a biotechnology company, focuses on developing personalized immune therapies for cancer. The company develops DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product candidate is the DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, that has completed Phase I clinical trials to treat inoperable solid tumors, as well as a range of types of cancers. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.